Nuzenio

Iii Harmoni

Iii Harmoni news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 4 latest news signals 4 publisher sources 100/100 entity strength

Latest news

Summit Therapeutics begins Phase II/III HARMONi-GU1 study of ivonescimab - YahooYahoo · Thu, 06 Aug 2026 10:46:44 GMTSummit Therapeutics Launches HARMONi-GU1 Trial for Ivonescimab in Bladder Cancer - The Clinical Trial VanguardThe Clinical Trial Vanguard · Thu, 06 Aug 2026 06:43:58 GMTSummit Therapeutics (NASDAQ: SMMT) launches Phase II/III HARMONi-GU1 bladder cancer study - Stock TitanStock Titan · Wed, 05 Aug 2026 11:32:48 GMTSummit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer - Business WireBusiness Wire · Wed, 05 Aug 2026 11:00:00 GMT

Timeline

Thu, 06 Aug 2026 10:46:44 GMTSummit Therapeutics begins Phase II/III HARMONi-GU1 study of ivonescimab - Yahoo
Thu, 06 Aug 2026 06:43:58 GMTSummit Therapeutics Launches HARMONi-GU1 Trial for Ivonescimab in Bladder Cancer - The Clinical Trial Vanguard
Wed, 05 Aug 2026 11:32:48 GMTSummit Therapeutics (NASDAQ: SMMT) launches Phase II/III HARMONi-GU1 bladder cancer study - Stock Titan
Wed, 05 Aug 2026 11:00:00 GMTSummit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer - Business Wire

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Iii Harmoni.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

4 distinct publisher/source names are currently connected to this entity page.